ClinicalTrials.gg
Active, not recruitingNCT06209281Mini-CHAMPUpdated Jul 30, 2025

A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops

A Phase 3 interventional study of Lower dose atropine sulfate eye drops and Low dose atropine sulfate eye drops in Myopia, sponsored by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. (formerly part of Lee's Pharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled May 2022, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
5th of 54
526 · median 144
Started
2022
with 4 others
Phase 3
13 of 54
5 open now
Primary completion
2023-08
later than 0 of 23 live
Registered
35th of 54
by date

Among the 54 studies testing atropine in Myopia, this one is the 5th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 3, reaches primary completion later than 0 of the 23 other live ones, and was the 35th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 226 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

This study was a randomized, double-blind, placebo-controlled, multicenter, superiority design, phase III clinical trial to compare the efficacy and safety of two low-concentration atropine sulfate eye drops versus placebo in delaying myopia progression in children.

Read the detailed description

Eligible subjects were screened and randomly assigned to the placebo control group, the lower dose group, and the lower dose group. Subjects received the study drug in both eyes, 1 drop each time, once every night before sleep, for continuous administration.A total of 526 subjects were planned to be enrolled。

Statistical analyses were performed with the use of SAS software, version 9.4, without any specific description. All statistical tests were two-sided at a 0.05 level.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Child (female or male) aged 6 to 10 years.
  2. Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measured by cycloplegic autorefraction.
  3. If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction.
  4. Anisometropia SER of \< 1.50 D as measured by cycloplegic autorefraction.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or syndrome that predisposed the subject to severe myopia (e.g.,Marfan syndrome, Stickler syndrome, retinopathy of prematurity).
  2. History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus,spherophakia).
  3. Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year).

    Use of cycloplegic drops for dilated ocular exam was allowable.

  4. Heart rate persistently (for more than 10 minutes) > 120 beats per minute.
  5. Allergy to study drugs.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
526 participants (actual)

Study arms

  • Experimental
    Experimental group 1

    1 drop each time, once every night at bedtime

    Drug: Lower dose atropine sulfate eye drops · Drug: Low dose atropine sulfate eye drops

  • Experimental
    Experimental group 2

    1 drop each time, once every night at bedtime

    Drug: Low dose atropine sulfate eye drops

  • Experimental
    control group

    1 drop each time, once every night at bedtime

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Cycloplegic Autorefraction(low)

    Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with low atropine versus placebo.

    Time frame: twelve months

Secondary outcomes

  1. Cycloplegic Autorefraction(lower)

    Group difference in the proportion of subjects eyes with myopia progression (SER) less than -0.50 D at M12 visit with lower atropine versus placebo.

    Time frame: twelve months

  2. Cycloplegic Autorefraction(SER)

    Between-group difference in the mean change from baseline in SER at visit M12

    Time frame: twelve months

Other outcomes

  1. Axial Length

    Between-group difference in the mean change from baseline in axial length at visit M12

    Time frame: twelve months

  2. Crystalline Lens Thickness

    Between-group difference in the mean change from baseline in crystalline lens thickness at visit M12

    Time frame: twelve months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2023, 15 months.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 17, 2024
StartActual
May 13, 2022
Primary completionActual
Aug 20, 2023
CompletionEst.
Dec 2025
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06209281
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
May 13, 2022
Primary completion
Aug 20, 2023
Completion
Dec 2025 (estimated)
Last update
Jul 30, 2025

Study contacts

Xiaomei Qu
principal investigator · Eye & ENT Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ophthalmic Solutions · Atropine

Start the discussion